Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline

作者：Praveen Vikas, Hans J. Messersmith, Carolyn C. Compton, Lynette Marie Sholl, Russell R. Broaddus, Anjee Davis, Maria Del Pilar Estevez-Diz, Rohan Garje, Panagiotis A. Konstantinopoulos, Aliza Leiser, Anne M. Mills, Barbara M. Norquist, Michael James Overman, Davendra P. S. Sohal, Richard Calvin Turkington, Tyler Paul Johnson · 发表于：Journal of Clinical Oncology · 年份：2023 · DOI：10.1200/jco.22.02462 · 被引用次数：127 · 研究领域：Genetic factors in colorectal cancer、Cancer Immunotherapy and Biomarkers、Multiple and Secondary Primary Cancers

PURPOSE The College of American Pathologists (CAP) has developed a guideline on testing for mismatch repair (MMR) and microsatellite instability (MSI) for patients considered for immune checkpoint inhibitor therapy. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS The CAP guideline was reviewed for developmental rigor by methodologists. An ASCO Endorsement Panel subsequently reviewed the content and the recommendations. RESULTS The ASCO Endorsement Panel determined that the recommendations from the CAP guideline, published on August 3, 2022, are clear, thorough, and based on the most relevant scientific evidence. ASCO endorses Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer. RECOMMENDATIONS Within the guideline, MMR immunohistochemistry (IHC), MSI polymerase chain reaction, and MSI next-generation sequencing are all recommended testing options for colorectal cancer, MMR-IHC and MSI-polymerase chain reaction for gastroesophageal and small bowel cancer, and only MMR-IHC for endometrial cancer. No recommendation in favor of any testing method over another could be made for any other cancer. Tumor mutational burden was not recommended as a surrogate for DNA MMR deficiency. If MMR deficiency ...